OS Therapies

Bone cancer
#Immunotherapy #Oncology #OS Therapies #Osteosarcoma #Phase II trial #Rare disease

One-year event free survival reported at osteosarcoma conference

OS Therapies has shared positive clinical trial data updates from its Phase IIb clinical trial of immunotherapy candidate OST-HER2 in fully resected, lung metastatic osteosarcoma.  The data were presented by Principal Investigator Dr Damon Reed at the MIB Factor Osteosarcoma Conference held in Salt Lake City, Utah… Read More

#Cancer Research #News